SJEPD031010_D1.RNA-Seq
EPN · EPN Tumor
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- EPN Tumor
- cancer_type
- EPN
- subtype
- EPN Tumor
- age_years
- 3.52
- e1_e2
- E2
- umap1_2d
- -6.451079693
- umap2_2d
- 1.438251733
- umap1_3d
- 0.347254597
- umap2_3d
- 4.612408426
- umap3_3d
- -0.207703652
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.520
- PROTEIN_SECRETION+0.510
- ADIPOGENESIS+0.340
- MITOTIC_SPINDLE+0.290
- ANDROGEN_RESPONSE+0.260
- CHOLESTEROL_HOMEOSTASIS+0.260
- FATTY_ACID_METABOLISM+0.240
- MTORC1_SIGNALING+0.230
- PEROXISOME+0.230
- UV_RESPONSE_DN+0.230
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.520
- ALLOGRAFT_REJECTION-0.480
- IL6_JAK_STAT3_SIGNALING-0.470
- TNFA_SIGNALING_VIA_NFKB-0.460
- INTERFERON_GAMMA_RESPONSE-0.450
- ANGIOGENESIS-0.400
- INFLAMMATORY_RESPONSE-0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.290
- KRAS_SIGNALING_DN-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD031319_D1.RNA-Seq | EPN | EPN Tumor | 0.878 |
| 2 | SJEPD031078_D2.RNA-Seq | EPN | Posterior Fossa EPN | 0.855 |
| 3 | BS_A46RDWGM | low-grade glioma | — | 0.845 |
| 4 | SRR12202452 | — | — | 0.844 |
| 5 | 877f3bcc-97ea-4b0e-9f61-98a9eaedd952 | — | — | 0.839 |
| 6 | MNG1176 | — | — | 0.838 |
| 7 | SJEPD030580_D1.RNA-Seq | EPN | EPN Tumor | 0.838 |
| 8 | 1D3FBEA0-9A7F-436C-AA71-366D4E11C43B | — | — | 0.831 |
| 9 | MNG730 | — | — | 0.831 |
| 10 | SJEPD030743_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.520 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.510 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.340 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.290 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.260 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| PEROXISOME | 0.230 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.230 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.180 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.170 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.140 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.050 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.010 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.010 | Idelalisib | — uncovered |